Pulmonary Sarcoidosis Pipeline Insight

DelveInsight’s, “Pulmonary Sarcoidosis - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Pulmonary Sarcoidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Pulmonary Sarcoidosis Understanding

Pulmonary Sarcoidosis: Overview

Sarcoidosis is a rare disease caused by inflammation. It usually occurs in the lungs and lymph nodes, but it can occur in almost any organ. Sarcoidosis in the lungs is called pulmonary sarcoidosis. It causes small lumps of inflammatory cells in the lungs. These lumps are called granulomas and can affect how the lungs work. The cause of pulmonary sarcoidosis is unknown. Experts think that bacteria, viruses, or chemicals might trigger the disease. It may also be genetic. The following are the most common symptoms of pulmonary sarcoidosis.


Symptoms may include: Shortness of breath, which often gets worse with activity, dry cough that will not go away, chest pain, wheezing. Pulmonary sarcoidosis is diagnosed through Chest X-ray, CT scan, pulmonary function tests, blood tests, bronchoscopy, bronchoalveolar lavage, lung biopsy. Treatment is generally done to control symptoms and improve the function of organs affected by the disease. Steroid medicine, such as prednisone, may help reduce inflammation. Other medicines, such as methotrexate, may be used in severe cases or if steroids don’t work.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Sarcoidosis R&D. The therapies under development are focused on novel approaches for Pulmonary Sarcoidosis.

Pulmonary Sarcoidosis Emerging Drugs Chapters

This segment of the Pulmonary Sarcoidosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Pulmonary Sarcoidosis Emerging Drugs


CMK 389: Novartis

CMK 389 acts as inhibitors of Interleukin 18. It is being developed by Novartis for Pulmonary sarcoidosis and is currently in phase II stage of development.


ATYR1923: aTyr Pharma

ATYR1923 is a potential first-in-class, disease modifying therapy for patients with severe inflammatory lung diseases with high unmet medical need. ATYR1923 works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent fibrosis. ATYR1923 is conducting a Phase 1b/2a clinical trial in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), a group of immune-mediated disorders that cause progressive fibrosis of the lung.

Further product details are provided in the report……..

Pulmonary Sarcoidosis: Therapeutic Assessment

This segment of the report provides insights about the different Pulmonary Sarcoidosis drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players working on Pulmonary Sarcoidosis

There are approx. 10+ key companies which are developing the Pulmonary Sarcoidosis. The companies which have their Pulmonary Sarcoidosis drug candidates in the most advanced stage, i.e. Phase III include, Corbus Pharmaceuticals.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Pulmonary Sarcoidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pulmonary Sarcoidosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Pulmonary Sarcoidosis therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary Sarcoidosis drugs.

Pulmonary Sarcoidosis Report Insights

  • Pulmonary Sarcoidosis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Pulmonary Sarcoidosis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

  • How many companies are developing Pulmonary Sarcoidosis drugs?
  • How many Pulmonary Sarcoidosis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Pulmonary Sarcoidosis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Sarcoidosis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Pulmonary Sarcoidosis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Pulmonary Sarcoidosis: Overview

  • Structure
  • Mechanism of Action

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Pulmonary Sarcoidosis– DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Pulmonary Sarcoidosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Pulmonary Sarcoidosis Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

CMK389: Novartis

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I/II)

  • Comparative Analysis

ATYR1923: aTyr Pharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

LAM–001: AI Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Pulmonary Sarcoidosis Key Companies

Pulmonary Sarcoidosis Key Products

Pulmonary Sarcoidosis- Unmet Needs

Pulmonary Sarcoidosis- Market Drivers and Barriers

Pulmonary Sarcoidosis- Future Perspectives and Conclusion

Pulmonary Sarcoidosis Analyst Views

Pulmonary Sarcoidosis Key Companies

Appendix

List of Table

Table 1: Total Products for Pulmonary Sarcoidosis

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Pulmonary Sarcoidosis

Figure 2: Late Stage Products

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• Novartis

• aTyr Pharma

• Relief Therapeutics

• AI Therapeutics

• SarcoMed USA

  • Tags:
  • Pulmonary Sarcoidosis Pipeline
  • Pulmonary Sarcoidosis clinical tri...
  • Pulmonary Sarcoidosis companies
  • Pulmonary Sarcoidosis drugs
  • Pulmonary Sarcoidosis therapies
  • Pulmonary Sarcoidosis treatment al...
  • Pulmonary Sarcoidosis pipeline dru...
  • Pulmonary Sarcoidosis pipeline com...

Forward to Friend

Need A Quote